← FDA DRUG APPROVALS

FDA ANDA · ANDA078128

ZIDOVUDINE

Sponsor: AUROBINDO PHARMA LTD

APPLICATION
ANDA078128
TYPE
ANDA
ORIGINAL APPROVAL
2006-03-27
LATEST ACTION
2025-04-21
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Prescription

Products

ZIDOVUDINEPrescription
ZIDOVUDINE 100MG · CAPSULE · ORAL

Approval history

2025-04-21Labeling · Supplement 18 · standardAP
2025-04-21Labeling · Supplement 22 · standardAP
2020-04-08Labeling · Supplement 15 · standardAP
2020-04-08Labeling · Supplement 13 · standardAP
2020-04-08Labeling · Supplement 14 · standardAP
2020-04-08Labeling · Supplement 12 · standardAP
2015-06-26Labeling · Supplement 11 · standardAP
2012-08-01Labeling · Supplement 8AP
2012-08-01Labeling · Supplement 9 · standardAP
2010-11-04Labeling · Supplement 5AP
2010-06-14Labeling · Supplement 4AP
2009-05-13Labeling · Supplement 3AP
2008-06-09Labeling · Supplement 2AP
2006-03-27OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →